コンテンツへスキップ
Merck

C6930

Sigma-Aldrich

モノクローナル抗サイトケラチンペプチド19抗体 マウス宿主抗体

clone A53-B/A2, tissue culture supernatant

別名:

Anti-CK19, Anti-K19, Anti-K1CS

ログイン組織・契約価格を表示する


About This Item

MDL番号:
UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

mouse

結合体

unconjugated

抗体製品の状態

tissue culture supernatant

抗体製品タイプ

primary antibodies

クローン

A53-B/A2, monoclonal

分子量

antigen 40 kDa

含みます

15 mM sodium azide

化学種の反応性

human

テクニック

indirect immunofluorescence: 1:50 using formalin-fixed, paraffin-embedded, human tissue sections
microarray: suitable

アイソタイプ

IgG2a

UniProtアクセッション番号

輸送温度

dry ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... KRT19(3880)

詳細

Monoclonal Anti-Cytokeratin Peptide 19 (mouse IgG2a isotype) is derived from the A53-B/A2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with mammary human carcinoma cell line MCF-7. Monoclonal Anti-Cytokeratin Peptide 19, known as clone A53-B/A2, or clone No. Ks 19.1, reacts with the rod domain of human cytokeratin peptide 19 (40 kDa), a cytoskeletal protein restricted to epithelial and carcinoma cells. Cytokeratin 19 is a member of the type I acidic subfamily. It is differentially expressed in various human tissues.

特異性

本抗体のクロ-ン番号はKS 19.1と表記される場合もあり、上皮細胞と癌細胞に限定の細胞骨格タンパク質であるサイトケラチンペプチド19のロッドドメインと反応します。種間交差性は極低か全くありません。抗体は単層上皮、および非角質化重層扁平上皮の基底細胞を標識します。単純癌の起源を識別する場合や、上皮性悪性腫瘍を細分類する手段として有用です。また、本抗体は口腔上皮の前癌病変のマ-カ-となることも確認されています。

免疫原

ヒト乳癌細胞株MCF-7。

アプリケーション

Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is also suitable:
  • for immunoblotting, for immunocytochemistry,
  • for immunofluorescence,
  • as a marker of premalignant lesions of the oral epithelium, to label cytokeratin in formalin-fixed or Carnoy-fixed, paraffin embedded tissue and in frozen sections of human tissue, to label simple epithelia and basal cells of noncornifying stratified squamous epithelia.

Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is suitable for microarray and indirect immunofluorescence at a dilution of 1:50 using formalin-fixed, paraffin-embedded and human tissue sections.

生物化学的/生理学的作用

Keratin, type I cytoskeletal 19 (40kDa protein) is also known as cytokeratin-19 (CK-19) or keratin-19 (K19). It is encoded by the KRT19 gene in humans. Keratin 19 is a type I keratin. Keratins are intermediate filament-forming proteins that provide mechanical support and perform a variety of additional functions in epithelial cells. K19 is expressed in a subset of hepatocellular carcinomas (HCC) with poor prognosis and is considered as a biliary/hepatic progenitor cell (HPC) marker. It is also a predictor of poorer prognosis for patients with human lung squamous cell carcinoma (SCC).
Monoclonal anti-cytokeratins are specific markers of epithelial cell differentiation and have been widely used as tools in tumor identification and classification.

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

WGK

nwg

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

C6930-.5ML:
C6930-VAR:
C6930-BULK:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Kasper, M., et al.
European Journal of Cancer, 23, 137-137 (1987)
Izabela Podgorski et al.
The American journal of pathology, 175(3), 1255-1269 (2009-08-25)
Bone metastasis is a hallmark of advanced prostate and breast cancers, yet the critical factors behind attraction of tumors to the skeleton have not been validated. Here, we investigated the involvement of cathepsin K in the progression of prostate tumors
Minati Satpathy et al.
Theranostics, 9(3), 778-795 (2019-02-28)
Cancer heterogeneity and drug resistance limit the efficacy of cancer therapy. To address this issue, we have developed an integrated treatment protocol for effective treatment of heterogeneous ovarian cancer. Methods: An amphiphilic polymer coated magnetic iron oxide nanoparticle was conjugated
Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles
Satpathy M, et al.
Theranostics, 9(3), 778-778 (2019)
R Moll et al.
Laboratory investigation; a journal of technical methods and pathology, 65(1), 74-86 (1991-07-01)
The expression of intermediate filament proteins, particularly individual cytokeratins (CKs), vimentin, and glial filament protein, was immunohistochemically investigated using frozen sections and Carnoy-fixed, paraffin-embedded tissue from normal fetal and adult human kidneys as well as from pathologically altered kidneys. In

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)